(Q34669339)

3 August 2017

1 reference

title

Cardiovascular effects of raloxifene: the potential for cardiovascular protection in women (English)

1 reference

3 August 2017

1 reference

Wenger NK

1

1 reference

3 August 2017

publication date

1 May 2002

1 reference

Diabetes, Obesity and Metabolism

3 August 2017

published in

1 reference

3 August 2017

volume

4

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

166-176

1 reference

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

The effect of raloxifene on coronary arteries in aged ovariectomized ewes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

Effects of LY117018 and the estrogen analogue, 17alpha-ethinylestradiol, on vascular reactivity, platelet aggregation, and lipid metabolism in the insulin-resistant JCR:LA-cp male rat: role of nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

1999 Bristol-Myers Squibb cardiovascular metabolic research award. Earl Davie, PhD, defined the system of blood coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

Raloxifene and estrogen reduces progression of advanced atherosclerosis--a study in ovariectomized, cholesterol-fed rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

The effect of aging on circulating levels of proinflammatory cytokines during septic shock. Norasept II Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

Design and methods of the Raloxifene Use for The Heart (RUTH) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00208.X

10.1046/J.1463-1326.2002.00208.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference